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Nonviral cationic polymers like chitosan can be combined with DNA to protect it from degradation. The chitosan is a
biocompatible,biodegradable,nontoxic,andcheappolycationicpolymerwithlowimmunogenicity.Theobjectiveofthisstudywas
to synthesize and then assess diﬀerent chitosan-DNA nanoparticles and to select the best ones for selective in vitro transfection in
human epidermoid carcinoma (KB) cell lines. It revealed that diﬀerent combinations of molecular weight, the presence or absence
of folic acid ligand, and diﬀerent plasmid DNA sizes can lead to nanoparticles with various diameters and diverse transfection
eﬃciencies.Theintracellulartraﬃcking,nuclearuptake,andlocalizationarealsostudiedbyconfocalmicroscopy,whichconﬁrmed
that DNA was delivered to cell nuclei to be expressed.
1.Introduction
Gene therapy is being applied to various health problems,
such as cancer, acquired immunodeﬁciency syndrome, and
cardiovascular diseases. The main challenge is to develop a
method that delivers the transgene to selected cells, where a
proper gene expression can be achieved. Several trials have
aimed at introducing genes straight into human cells, focus-
ing on diseases caused by single-gene defects, such as cystic
ﬁbrosis [1], hemophilia [2], adenosine deaminase deﬁciency
[3], muscular dystrophy [4], and sickle cell anemia [5].
Ideally, gene therapy must protect DNA against degra-
dation by nucleases in intercellular matrices so that the
disposition of macromolecules is not aﬀected. Transgenes
should be brought across the plasma membrane and into
the nucleus of targeted cells but should have no detrimental
eﬀects. Hence, interaction with blood components, vascular
endothelial cells, and uptake by the reticuloendothelial
system must be avoided [6].
For gene therapy to succeed, small-sized systems must
internalize into cells and pass to the nucleus. Also, ﬂexible
tropisms allow applicability to a range of disease targets.
Last but not least, such systems should be able to escape
endosome-lysosome processing for endocytosis [7].
Viral gene therapy consists of using viral vectors which,
given their structure and mechanisms of action, are good
candidates or models to carry therapeutic genes eﬃciently,
leading to long-term expression [8, 9]. They have the natural
ability to enter cells and express their own proteins. Now-
adays, most viral vectors used are retroviruses, herpes virus,
adenoviruses, and lentiviruses [10]. However, viral vectors2 ISRN Pharmaceutics
can cause several problems to patients, namely, toxicity, on-
cogenic eﬀects, and immune and inﬂammatory responses.
Because of safety and cost concerns, nonviral vectors have
gained a lot of attention in the literature [6, 7].
Nonviral gene therapy has been explored by physical
approaches (transfer by gene gun, electroporation, ultra-
sound-facilitated and hydrodynamic delivery) as well as che-
mical approaches (cationic lipid-mediated gene delivery, and
cationic polymer-mediated gene transfer) [11].
Synthetic and natural cationic polymers (positively
charged) have been widely used to carry DNA (negatively
charged) and condense it into small particles, facilitating cel-
lular internalization via endocytosis through charge-charge
interactions with anionic sites on cell surfaces. In this cat-
egory, we include polyethylenimine, polyamidoamine, and
polypropylamine dendrimers, polyallylamine, chitosan, cat-
ionic dextran, cationic peptides, and proteins [6, 12]. Nonvi-
ral delivery systems for gene therapy have been increasingly
proposed as safer alternatives to viral vectors because they
evokeaminimalhostimmuneresponse,arestableinstorage,
easy to produce in large quantities, and are of low cost [13].
Chitosan (Ch) is a biocompatible, biodegradable, non-
toxic, and cheap polycationic polymer with low immuno-
genicity. Positively charged Ch can be easily complexed with
DNA and protected from nuclease degradation [7, 14]. It is
also hypoallergenic and has natural antibacterial properties.
Sonication and organic solvents are not required for its pre-
paration, which minimizes possible damage to DNA during
complexation. Ch (α (1→4) 2-amino-2-deoxy-β-D-glucan)
is produced commercially by deacetylation of chitin, the
structural element in the exoskeleton of crustaceans (e.g.,
crab, shrimp) [15, 16]. This polymer has a weak base; con-
sequently, in acidic media, the amine groups will be posi-
tivelycharged,conferringhigh-chargedensitytothepolysac-
charide[7].Thecationiccharacteristicofchitosanisacrucial
parameter for complex formation.
Folicacid(FA)receptors(FR)areoverexpressedonmany
human cancer cell surfaces, and the nonepithelial isoform
FR(β) is expressed on activated synovial macrophages pre-
sent in large numbers in rheumatoid arthritis (RA) [17].
FA-mediated transfection has been shown to facilitate
DNA internalization into cells through membrane receptors
both in vitro and in vivo. Another strategy for improving
transfection is to take advantage of the mechanism of folate
uptake by cells to promote targeting and internalization,
hence improving transfection eﬃciency [18]. FA is appealing
as a ligand for targeting cell membranes and allowing nano-
particle endocytosis via FR for higher transfection yields.
Importantly, the high aﬃnity of folate for binding to its
receptor(1nm)anditssmallsizemakeitidealforspeciﬁccell
targeting. Moreover, the ability of FA to bind its receptor for
endocytosis is not altered by covalent conjugation of small
molecules [19].
The objective of this study was to synthesize and then
assess diﬀerent Ch nanoparticles and to select the best suited
ones for selective in vitro transfection in human epidermoid
carcinoma (KB) cell lines.
2.MaterialsandMethods
2.1. Synthesis of Ch Nanoparticles. Low-molecular-weight
(LMW) Ch (Wako-10, degree of deacetylation (DDA) =
89%, amine phosphate ratio N:P of 3:1) was purchased
fromWakoChemicals(Richmond,VA,USA).Chofdiﬀerent
molecular weights (MWs) (5 kDa: Ch5, 25 kDa: Ch25, and
50kDa:Ch50)wereselectedtocreatediﬀerentnanoparticles.
FA (MW = 441.41Da) was purchased from Sigma-
Aldrich Chemicals (St. Louis, MO, USA). α-amino, ω-carbo-
xyl poly(ethylene glycol) (NH2-PEG-COOH, MW = 3,400
Dalton) was obtained from Shearwater Inc. (Dallas, Texas,
USA). Ch was further deacetylated by treatment with con-
centrated NaOH solution (50%) to obtain ∼89% deacetyla-
tion according to a reported procedure [20].
To prepare Ch-PEG-folate conjugate, FA was combined
with Ch through the PEG arm. FA was ﬁrst attached to NH2-
PEG-COOH via well-known carbodiimide chemistry to give
folate-PEG-COOH. Then, folate-PEG-COOH was again ac-
tivated by N,N -dicyclohexylcarbodiimide and N-hydroxy-
succinimide (NHS) for conversion to the reactive interme-
diate folate-PEG-CO-NHS and subsequently grafted onto
Ch to achieve Ch-PEG-folate conjugate [21]. The level of
folate-PEG incorporation was determined to be 1.1mol%
with respect to the glucosamine unit of chitosan by UV-Vis
spectroscopy using FA as standard. (The extinction coeﬃ-
cient (λ363nm) of FA was 6,165M−1cm−1 in pH 7.4 phos-
phate buﬀer (0.1M).) A stock solution of 0.1% Ch or Ch-
PEG-FA was prepared in 25mM acetic acid, under contin-
uous stirring at 37◦C, and then adjusted to pH 5.0 with
1MNaOH.100μg/mLDNAsolutionwasbuﬀeredin43mM
Na2SO4 [22].
The plasmids used in this study were VR1412 and
pEGFP-C3. pEGFP-C3 is a nonviral, mammalian plasmid. It
has a CMV promoter and backbone size of 4,727bp. It codes
forGFP(greenﬂuorescentprotein) thatallowsresearchersto
optically detect speciﬁc types of cells in vitro or in vivo [23].
The plasmid DNA VR1412, encoding the β-galactosidase
(β-gal) reporter gene with a CMV promoter and a backbone
size of 8,100 kb, was obtained from VICAL Inc. (San Diego,
CA, USA) [23, 24].
Mass quantity plasmids (VR1412 and pEGFP-C3) were
prepared with commercial kits (Mega Kits, Qiagen Missis-
sauga, ON, Canada), and ﬁnally suspended in sterile water.
The integrity of DNA plasmid was analyzed by 0.8% agarose
gel electrophoresis and quantiﬁed (DNA concentration) by
UV spectrometryat 260nm. Allprocedures wereundertaken
according to manual instructions [25].
Ch solutions were heated at 55◦C for 1 minute; then,
nanoparticle synthesis was carried out by mixing an equal
volume of Ch and DNA stock solutions at room temperature
(Ch:DNA ratio = 1:1), stirred for 30 minutes and allowed
to stand for 1 hour before transfection [25]. Four types of
nanoparticles were synthesized: Ch-GFP, Ch-PEG-FA-GFP,
Ch-β-gal, and Ch-PEG-FA-β-gal. Ch5, Ch25, and Ch50 are
used for each type, giving a total of 12 diﬀerent nano-
particle complexes. Ch nanoparticles were compared to
Lipofectamine 2000 (LF), a commercially available lipid
vector, which is considered to be the gold standard for itsISRN Pharmaceutics 3
high transfection eﬃciency. LF was combined with DNA by
mixing with a respective volume ratio of 1:3.25μLa tr o o m
temperature. All measurements were collected in triplicate,
and each experiment repeated 3 times [7].
2.2. Electrophoresis Gel Analysis. Agarose gel electrophoresis
is a technique that separates DNA or RNA molecules by size.
It is performed by moving negatively charged nucleic acid
molecules through an agarose matrix with an electric ﬁeld.
Electrophoresis gel analysis contributes to the assessment
of gene condensation with Ch and DNA integrity. Intact and
complexed genes are seen and analyzed [25].
2.3. Nanoparticle Size. We measured the nanoparticle sizes
of Ch-GFP, Ch-PEG-FA-GFP, Ch-β-gal, and Ch-PEG-FA-
β-gal with Ch5, Ch25, and Ch50 kDa in an ALV/CGS-3
Compact Goniometer System for dynamic light scattering
ﬁxed at a 90◦ angle with a wavelength of λ = 632.8nm.The
results indicated the distribution curve and diameter of the
nanoparticles in nm [16].
2.4. Zeta Potential. Zeta potential allows the measurement
of overall surface charge of nanoparticles, which represents
a critical factor in their interaction with cellular membranes.
This study was performed at 25◦C, using a Malvern Zetasizer
4 (Malvern Instruments Ltd., Malvern, UK) and green
disposable cuvettes for the zetasizer and nanoseries.
2.5. Cell Preparation for In Vitro Transfection. In this study,
we selected KB cells for their unlimited division capacity and
overexpression of FR [26]. The cells were obtained from the
American Type Culture Collection (Rockville, MD, USA).
They were inoculated at a density of 14 × 105 cells/well (in
6-well plates) with RPMI medium 1640 containing 10% of
fetal bovine serum (FBS) and 1% penicillin. The plates were
kept in a cell culture incubator under 5% CO2 at 37◦C.
2.6. Cell Transfection. In vitro transfection eﬃciency was
undertaken in KB cells incubated in 6-well plates with
600μL of Ch nanoparticle complexes (Ch-GFP, Ch-PEG-FA-
GFP, Ch-β-gal, and Ch-PEG-FA-β-gal) with Ch5, Ch25 and
Ch50kDa. The cells are incubated for 2 hours at 37◦Cw i t h
1,400μL of fresh antibiotic-free RPMI medium 1640, serum,
and FA, then examined by optical microscopy.
Positive (cells transfected with LF or DNA) and negative
(nontransfected cells) controls were used. Gene expression
was detected 48 hours after transfection [7].
2.7. GFP Expression. GFP is composed of 238 amino acids
(26.9 kDa), and ﬂuoresces green when exposed to blue light
under a ﬂuorescence microscope equipped with an analog
camera. In cellular and molecular biology, it is frequently
deployed as a reporter of gene expression.
The ﬂuorescence emitted by KB cells showing GFP
expression was detected with Photon Technology Interna-
tional at an excitation wavelength of 484 nm and emission
of 510nm.
Each sample was measured 10 times. Numerical results
were analyzed by FeliX 1.42.exe. Photos of cells were taken to
complete and conﬁrm the quantitative results [13].
2.8. β-Gal Expression. The VR1412 gene codes for β-gal, an
enzyme that catalyzes the hydrolysis of β-galactosides into
monosaccharides.
β-gal activity was measured with Sigma kits (Sigma-
Aldrich, Oakville, ON, Canada) and compared to total
protein (pg β-gal per mg of cellular protein).
Total protein content in the solution was quantiﬁed by
bicinchoninic acid assay (Pierce, Rockford, IL, USA). In this
assay, 2 molecules of bicinchoninic acid chelated a single
Cu1+ ion, forming a purple water-soluble complex that
strongly absorbed light at 562nm.
The results of β-gal expression were read on 96-well
plates by a EL-800 Universal Microplate Reader (Bio-Tek In-
struments Inc., Winooski, VT, USA) at a wavelength of
420nm [25].
2.9. Cell Viability. Cytotoxicity (nanoparticle eﬀects on
cell viability) was studied by 3-[4,5-dimethylthiazol-2-yl]-
2,5diphenyl tetrazolium bromide assay, a standard colori-
metric assay for measuring the activity of enzymes that re-
duce yellow MTT to formazan in living cell mitochondria,
giving it a purple color. The absorbance of this colored solu-
tion can be quantiﬁed by measurement with a spectropho-
tometer at a certain wavelength (usually between 500 and
600nm). Coloration intensity was proportional to the num-
ber of living cells because reduction takes place only when
mitochondrial reductase enzymes are active.
ViabilitywasmeasuredwiththeEL-800UniversalMicro-
plate Reader at 570nm, in 96-well plates [25].
2.10. Intracellular Traﬃcking, Nuclear Uptake, and Localiza-
tion. KB cells were incubated with Ch25-PEG-FA-β-gal na-
noparticle complexes for 2 hours at 37◦C, ﬁxed, and ex-
amined by confocal microscopy. Plasmid DNA was bound
with propidium iodide (PI) (red), and stained DNA was pu-
riﬁed before nanoparticle synthesis. Endosomes and lyso-
somes were immunolabeled with antiearly endosome maker,
lysosomal-associated membrane protein-1, and ﬂuorescent-
labeledanti-mouseantibodies(green).DAPIstaininglocated
cell nuclei (blue).
2.11. Statistical Analyses. A l lv a l u e sw e r ee x p r e s s e da sm e a n s
± standard deviation and analyzed by unpaired Student’s t-
test and/or one-way ANOVA with P ≤ 0.05 considered as a
statistically signiﬁcant diﬀerence.
3. Results
3.1. Synthesis of Folate-PEG-Chitosan. The feasibility of
folate-mediated targeting of chitosan was investigated after
FA coupling to chitosan with PEG as spacer. The structure of
Folate-PEG-chitosan conjugate is illustrated in Figure 1.
3.2. Nanoparticle Characterization. Agarose gel electropho-
resis of β-gal (Figures 2(a)) and GFP (Figure 2(b))a sw e l la s
Ch-DNA and Ch-PEG-FA-DNA nanoparticles with diﬀerent
MW Ch presented dense bands, conﬁrming complex forma-
tion (Figures2(a) and 2(b)— 3 ,4 ,5 ,6 ,7 ,8 ) .P a r t i c l es i z e s
were found to be in the range of 100 to 300nm, depending
on the plasmid and presence/absence of FA (Figure 3). Zeta4 ISRN Pharmaceutics
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Figure 1: Molecular grafted structure of chitosan-PEG-FA complex. (1) Chitosan; (2) PEG; (3) folic acid.
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Figure 2: Agarose gel electrophoresis. (a) Chitosan nanoparticles with VR1412 β-gal plasmid DNA. (b) Chitosan nanoparticles with GFP
plasmid DNA. Lane 1: ladder; lane 2: naked DNA; lane 3: Ch-DNA nanoparticule with a Mw = 5KDa chitosan; lane 4: Ch-PEG-FA-DNA
nanoparticule with a Mw = 5KDa chitosan; lane 5: Ch-DNA nanoparticule with a Mw = 25KDa chitosan; lane 6: Ch-PEG-FA-DNA with
aM w= 25KDa chitosan; lane 7: Ch-DNA with a Mw = 50KDa chitosan; lane 8: Ch-PEG-FA-DNA nanoparticule with a Mw = 50KDa
chitosan.
potential remained stable for all nanoparticles with average
values around +15mV. MTT viability studies revealed low
cell toxicity compared to naked DNA and LF (Figure 4).
3.3. In Vitro Transfection Eﬃciency in KB Cells. Gene expres-
sionwasmostsigniﬁcantwithCh25-PEG-FA-DNAnanopar-
ticles (Figures 5(a), 5(b),a n d5(c)). β-gal expression was
diﬀerent among the various groups. Signiﬁcant diﬀerences
w e r eo b s e r v e dw h e nt h ee x p e r i m e n t a lg r o u p s( 3 ,5 ,6 ,a n d7 )
were compared to the negative controls (1) (Figure 5(a)).
By comparing the transfection rate using LF with the
Ch25-PEG-FA-DNA nanoparticle, we found no signiﬁcant
diﬀerence(P = NS)betweenthe2groups(Figure 5(b):c ol-
umn 6 and Figure 5(b): column 9).
Figure 5(c) illustrates the overall results and greater
transfection eﬃciency of GFP gene expression in KB cellsISRN Pharmaceutics 5
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Figure 3: Distribution function of nanoparticles sizes (diameter in nm). (1) Ch5-β-gal: 114.27 ± 20.08nm; (2) Ch5-PEG-FA-β-gal:
150.03 ± 9.76nm; (3) Ch5-GFP: 223.83 ± 11.54nm; (4) Ch5-PEG-FA-GFP: 278 ± 27.22nm; (5) Ch25-β-gal: 127.67 ± 16.21nm;
(6) Ch25-PEG-FA-β-gal: 134.84 ± 14.13nm; (7) Ch25-GFP: 151.43 ± 9.35nm; (8) Ch25-PEG-FA-GFP: 204.33 ± 5.91nm; (9) Ch50-
β-gal: 111.94 ± 20.75nm; (10) Ch50-PEG-FA-β-gal: 247.34 ± 18.33nm; (11) Ch50-GFP: 160.21 ± 6.82nm; (12) Ch50-PEG-FA-GFP:
302.08 ± 34.13nm (P<0.05, n = 5).
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Figure 4: Cells viability treated with chitosan nanoparticules (a) containing the VR1412 β-gal plasmid DNA. Group 1: negative control (KB
cells); Group 2: naked DNA; Group 3: Ch-DNA nanoparticule with a Mw = 5KDa chitosan; Group 4: Ch-PEG-FA-DNA nanoparticule with
aM w= 5KDa chitosan; Group 5: ch-DNA nanoparticule with a Mw = 25KDa chitosan; Group 6: Ch-PEG-FA-DNA with a Mw = 25KDa
chitosan; Group 7: Ch-DNA with a Mw = 50KDa chitosan; Group 8: Ch-PEG-FA-DNA nanoparticule with a Mw = 50KDa chitosan; Group
9: Lipofectamine. (b) Chitosan nonconjugated with DNA, Group 1: negative control; Group 3: Mw = 5KDa chitosan; Group 4: Mw = 5KDa
chitosan combined with FA; Group 5: Mw = 25KDa Chitosan; Group 6: Mw = 25KDa chitosan combined with FA; Group 7: Mw = 50KDa
chitosan; Group 8: Mw = 50KDa chitosan combined with FA; Group 9: lipofectamine. ∗Statistical signiﬁcant diﬀerences compared with
positive control (P< 0.05).
with Ch25-PEG-FA-DNA. The density of ﬂuorescent cells
compared to existing 14.105 c e l l si ne a c h6 - w e l lp l a t ew a sa n
indicator of the transfection rate.
3.4. Intracellular Traﬃcking, Nuclear Uptake, and Localiza-
tion. We localized endosomes and lysosomes stained in
green, DNA in red, and nuclei in blue of KB cells transfected
with Ch25-PEG-FA-β-gal nanoparticles. VR1412 plasmid
bound PI and appeared in red. After nuclei isolation, we
observedred,coloration,whichconﬁrmedthatDNAwasde-
livered to cell nuclei to be expressed (Figure 6).
4. Discussion
We have shown that biodegradable cationic polymers such
as Ch have the potential for DNA complexation and may be
usedasnonviralvectorsforgenetherapy.Theﬁrstaimofthis6 ISRN Pharmaceutics
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Figure 5: Expression of (a) VR1412 β-gal, (b) GFP in KB cells and (c) KB cells expressing GFP seen with ﬂuorescent microscopy
(magniﬁcation × 10) Group 1: negative control (KB cells); Group 2: Naked DNA; Group 3: Ch-DNA nanoparticule with a Mw = 5KDa
chitosan; Group 4: Ch-PEG-FA-DNA nanoparticule with a Mw = 5KDa chitosan; Group 5: Ch-DNA nanoparticule with a Mw = 25KDa
chitosan; Group 6: Ch-PEG-FA-DNA with a Mw = 25KDa chitosan; Group 7: Ch-DNA with a Mw = 50KDa chitosan; Group 8: Ch-PEG-
FA-DNA nanoparticulewith a Mw = 50KDa chitosan; Group 9: lipofectamine coupled with DNA; Group 10: KB cells seen with optical
microscopy; Group 11: KB cells seen with ﬂuorescent microscopy; Group 12: negative control, nontreated KB cells seen with ﬂuorescent
microscopy. ∗Statistical signiﬁcant diﬀerences compared with positive control (P<0.05).
study was to design and then evaluate Ch nanoparticles with
diﬀerent characteristics.
WealsofoundChandChnanoparticlestobenontoxicin
a range of toxicity tests. We also demonstrated the ability of
Ch-DNA and Ch-PEG-FA-DNA complexes to condense and
deliver plasmid DNA in human KB cells.
In our study, transfection eﬃciency depended on Ch’s
MW, the presence or absence of FA, and the nature of the
combinedgene.Ch25-PEG-FA-DNAshowedbetterGFPand
β-gal expression in vitro.
4.1. Nanoparticle Characteristics. Agarose gel electrophoresis
conﬁrmed the strong attachment of DNA to Ch and Ch-
PEG-FA. The synthesis of Ch-DNA complexes was facilitated
by attraction between free amino groups on the polymer and
negatively charged phosphates found on DNA [24]. Lanes
showing no unbound DNA explain the strong attachment
of Ch-β-gal, Ch-GFP, Ch-PEG-FA-β-gal, and Ch-PEG-FA-
GFP complexes. The interaction involved in the complexes
was mainly electrostatic [7]. Previous studies suggested that
covalent linkage of FA with Ch did not aﬀect electrostatic
attachment with DNA. After digestion with chitosanase and
lysozyme, intact plasmid DNA was released from Ch [25],
suggesting that the synthesis conditions and FA covalent
linkage with Ch did not aﬀect the integrity of condensed
DNA. Usually, DNA has to maintain its supercoiled circular
form for optimal gene expression. Nanoparticle complexes
must provide DNA protection from physical, chemical,
and enzymatic degradation. During the preparation of
nanoparticles, there is a risk of damaging supercoiled DNA
and converting it to linear or even fragmented DNA [27].
This was not observed in our experiments.
We suggest that the size of 12 diﬀerent nanoparticles
depends on the size of the DNA molecule and the conjugate
(PEG-FA)addedtopromotetargetingandinternalizationon
transfection. In the presence of FA attached to Ch through
the PEG arm, we expected an increase in nanoparticle size.
The MW of Ch did not signiﬁcantly aﬀect nanoparticle size.
Also, zeta potential remained stable around +15mV for all
nanoparticle samples (N:P ratio of 3:1, DDA = 89%), and
no impact on size was observed.
The normal distribution of Ch-DNA and Ch-PEG-FA-
DNA nanoparticle diameters makes this study unique as very
few has elaborated the Gaussian distribution of Ch nanopar-
ticle size [28]. It has been suggested that polydispersity of the
C husedt oc o mple xDN Acanha v eane ﬀectonthesize of the
resulting particle [27].ISRN Pharmaceutics 7
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Figure 6: Intracellular traﬃcking in KB cells. KB cells were incubated with chitosan nanoparticle complex for 2 hours 37◦C, ﬁxes and
examined by confocal microscopy. A1 and B1: endosomes and lysosomes immunolabeled with antiearly endosome maker (EEA-1) and
lysosomal-associated membrane protein1 (LAMP-1) and ﬂuorescent-labeled anti-mouse antibodies appear green. A2 and B2: plasmid DNA
binded with Propidium Iodide (PI) appears red. Stained DNA were puriﬁed before nanoparticle; synthesis. A3 and B3: bleu located nuclei of
cells as DAPI staining. Under the same condition of transfection with chitosan nanoparticule, A1, B1: endosomes and lysosomes A4 and B4.
Superposition of diﬀerent staining for a three-dimensional image reconstruction. (c) Whole cells, (d) nuclei of KB were isolated. Red shows
plasmid DNA beforehand stained with PI; no any staining is there for nuclear DNA.
Two properties are necessary to assure nanoparticle
uptake by cells: zeta potential (or surface charge) and size.
Previous studies have conﬁrmed that DDA, MW, N:P ratio,
andpHdonotinﬂuencecomplexsize[29].Nanoparticlesize
is one of the variables for favorable cellular uptake. Nano-
particles of smaller size have the advantage of entering cells
more easily by endocytosis or pinocytosis and crossing nu-
clear-pore complexes, thereby increasing the transfection
rate[15].Ithasbeenproposedthatforpolycation-DNAgene
delivery systems to enter cells, a size requirement below 100
nm is necessary [24].
Our team and others have previously demonstrated that
a positive surface charge allows electrostatic interaction be-
tween negatively charged cellular membranes and positively
charged nanoparticles [16]. Ch-DNA nanoparticle size was
indirectly proportional to the charge ratio (N:P) up to
12mV, while zeta potential was directly proportional to it
(N:P).
A ﬁne balance must be achieved between extracellular
DNAprotection(betterwithhighMWorHMW)versuseﬃ-
cient intracellular unpacking (better with LMW) to obtain
high levels of transfection. HMW Ch can be depolymerized
by diﬀerent methods, such as ultrasound, heat, enzymatic
hydrolysis, and chemical hydrolysis. Depolymerization of Ch
by nitrous acid is becoming a favored technique since it is
economical, rapid and can be controlled to produce Ch of
preselected size [29].
In this study, the eﬀect of Ch-DNA and Ch-PEG-FA-
DNA nanoparticles on KB cell viability was compared to
naked DNA and LF. There was no signiﬁcant change in cell
viability between Ch-treated and untreated KB cells. KB cells
incubated with Ch25-PEG-FA-β-gal nanoparticles showed
100% cell viability. Also, 90% to 100% cell viability was
observed in cells incubated with Ch25-PEG-FA or Ch50-
PEG-FA. All Ch nanoparticule combinations showed much
lower cytotoxicity compared to LF.8 ISRN Pharmaceutics
These results and previous studies conﬁrm that Ch and
Ch nanoparticles are nontoxic in a range of toxicity tests,
both in vitro [24] and in experimental animals [13].
4.2. In Vitro Transfection Eﬃciency of Ch Nanoparticles in KB
Cells. We compared transfection eﬃciency to diﬀerent MW
Chs (5, 25 and 50kDa) and the presence or absence of PEG-
FA. Diﬀerent LMW Chs were used because it was previously
demonstrated that DNA can be more easily released from
them [30].
The choice of plasmid DNA was based on the evaluation
method of gene expression and its corresponding size, either
VR1412 (β-gal reporter vector for assaying β-gal activity)
or GFP (emitting green ﬂuorescence when expressed). KB
cells were mainly chosen because of FR overexpression [26].
The transfection eﬃciency of Ch nanoparticles has been
studied previously in Cos-1 cells, HeLa cells, Hep-G2 cells,
and 293human embryonic kidney cells [13, 24].
Gene expression was signiﬁcantly higher with Ch25-
PEG-FA-DNA nanoparticles. No signiﬁcant diﬀerences were
seen when comparing the rate of transfection with LF (pos-
itive control) to Ch25-PEG-FA-DNA nanoparticles.
The transfection eﬃciency of nonviral vectors may de-
pend on several factors, such as chemical polycation char-
acteristics (DDA, MW, N:P ratio, Ch:DNA ratio, and pH),
size and composition of complexes, interaction between cells
and complexes, and cell type [15]. We have studied the in-
ﬂuence of Ch MW while other factors were kept constant
(DDA = 89, pH = 7.4).
It has been demonstrated that gene expression levels
are closely related to polymer MW [29]. Binding aﬃnity
and complex formation between oppositely charged macro-
molecules are strongly dependent on the valence of each
molecule, with low valence yielding only weak binding. The
reduction in Ch valence at LMW has been shown to de-
crease its binding aﬃnity for DNA and to increase DNA de-
complexation and gene expression [29].
The percentage of transfected cells signiﬁcantly depends
on the type of complexes used and is sensitive to Ch MW. It
was suggested that high MW Ch may form very stable com-
plexes, making it hard to express a given gene sequence since
they may not be disassembled once inside the cell. On the
other hand, at critical LMW, Ch cannot fully condense DNA
[29].
The more eﬃcient cell transfection of Ch-DNA com-
plexes compared to naked DNA may be due to a zipper-
like association of excess positive charges of the complexes
with the negatively charged cell surface. This interaction may
resultinadsorptiveendocytosisandmembranestability[27].
PEG-FA nanoparticle complexes (Ch25-PEG-FA-DNA)
have been shown to facilitate DNA internalization into cells.
High-aﬃnity FR binding is retained when FA is covalently
linked via its γ-carboxyl group to a foreign molecule. The
presence of FR in certain diseases helps to target and deliver
DNA to diseased cells while avoiding uptake into normal
cells. It is a highly speciﬁc and versatile technique that can
be applied to a wide variety of drugs and diseases. It is
a good strategy to transfect several cancer cell types (such
as ovarian and breast cancers) [31]. Activated macrophages
are responsible for the progression of autoimmune diseases
such as RA, psoriasis, ulcerative colitis, and lupus [18, 19].
ActivatedmacrophagesinRAoverexpressmembraneFR[18,
32] and represent a potential opportunity for FR-targeted
gene therapy. The presence of the FA group seems to help
internalization in KB cells, probably through their FR.
5. Conclusion
We synthesized and then assessed Ch nanoparticles with
diﬀerent characteristics and selected the one best suited for
selective transfection eﬃciency in human KB cells in vitro.
Tothebestofourknowledge,thisistheﬁrststudytoconﬁrm
thatnanoparticuleswithCh25complexedtoFAobtainbetter
transfection eﬃciency in cells overexpressing FR. Our system
should have the potential of being employed as speciﬁc cell-
targeting systems with cells having high FA occurrence.
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